What FAI does to hip cartilage — and why it matters early

The hip is a ball-and-socket joint, and in most people that socket glides smoothly through a full range of movement. In femoroacetabular impingement (FAI), however, a bony overgrowth — at the femoral head-neck junction (cam lesion), around the acetabular rim (pincer lesion), or both — means bone contacts cartilage at the wrong angle with every step and rotation. That repeated pinching gradually shears the acetabular cartilage at the rim, where the labrum and cartilage converge.

The difficulty is that hip articular cartilage has no blood supply and almost no capacity to repair itself. A focal Grade III or IV lesion — a deep fissure or full-thickness loss — will not fill in spontaneously. Without intervention, focal damage tends to expand into a broader zone of wear and the joint space begins to narrow.

The German Cartilage Registry, drawing on 2,725 patients who underwent FAI and cartilage surgery, found that cartilage damage grade was the only independent statistically significant predictor of both clinical outcome and total hip replacement-free survival (p = 0.001–0.002), with 90–93% THA-free survival at five years in patients treated before advanced wear had set in.

That evidence points to a practical window for intervention. Focal lesions in active adults — particularly those in their forties or fifties — are far more amenable to cartilage-preserving treatment than diffuse Tönnis Grade 2–3 osteoarthritis, where options narrow considerably. Acting while the surrounding joint remains largely healthy is the aim; the Mazek 2021 cohort confirmed that patients who already had Grade 2–3 osteoarthritis at the time of treatment achieved poor results.

Who is suitable for ChondroFiller injection

Three factors determine whether ChondroFiller injection is likely to help a particular patient with FAI-related hip damage: the nature of the cartilage lesion itself, the state of the surrounding joint, and whether the hip as a whole can support scaffold-based repair.

Who tends to benefit most

Patients who fit the strongest candidate profile share a few key features:

• A focal, full-thickness cartilage defect — typically ICRS Grade III or IV — confirmed on detailed hip MRI, with a defect area broadly within the 2–6 cm² range the scaffold is designed to address
• FAI as the underlying cause, meaning the damage is concentrated at the rim or contact zone rather than spread across the whole joint surface
• Surrounding articular cartilage that remains largely intact, with healthy margins bordering the lesion
• Tönnis Grade 0 or 1 on pre-procedure imaging, confirming that wider joint degeneration has not yet taken hold
• Structurally sound subchondral bone beneath the defect

Active adults — broadly in their forties to mid-sixties — who have tried conservative measures without sufficient relief make up the most common referral group.

Where the injection is not appropriate

As noted above, pre-existing Tönnis Grade 2–3 osteoarthritis is a recognised contraindication: in published outcome data, results in this group are poor. Diffuse cartilage loss spanning multiple joint surfaces — rather than a single focal defect — also falls outside the treatment's intended scope.

Not qualifying for ChondroFiller injection does not exhaust the options. Depending on the degree and pattern of wear, other cartilage restoration approaches or a joint replacement pathway may be a more appropriate next step; a specialist assessment determines which direction makes sense.

MRI is a prerequisite before any decision is made. Hip pain alone does not confirm focal cartilage damage, and a detailed scan is the tool that maps lesion size, location, and OA stage — the information on which candidacy ultimately rests.

How the ChondroFiller injection works

At its core, ChondroFiller is a purified Type I collagen hydrogel — a liquid at room temperature that transforms into a firm, three-dimensional scaffold within approximately three to five minutes of contact with body heat inside the joint. It contains no living cells, no donor tissue, and no material from another person; it is a CE-marked, acellular medical device that acts as a biological framework rather than a replacement tissue.

The injection itself

Delivery takes place in a clinic setting, without a general anaesthetic or an operating theatre. Under real-time ultrasound imaging, a fine needle is guided to the cartilage defect in the hip and the collagen solution is placed directly into the lesion, where it polymerises in situ to fill the damaged area.

Ultrasound guidance is clinically essential here, not merely reassuring. The hip lies beneath 4–8 cm of soft tissue, with the femoral artery approximately 1.9 cm medial to the anterior capsule, the femoral vein around 1.7 cm medial, and the femoral nerve roughly 2.3 cm lateral. A 2016 systematic review by Hoeber et al. (120 citations) found that landmark-guided hip injections achieved accurate intra-articular placement in only 72% of cases, against 100% for image-guided technique (p<0.0001). In this anatomy, precision is not optional.

What happens inside the hip

Once the scaffold sets, it provides a stable matrix that recruits the patient's own progenitor cells — drawn from surrounding synovial tissue and subchondral bone — to migrate in and begin the repair process. This mechanism is called matrix-induced chondrogenesis: the scaffold acts as a framework that the body's own repair cells move into, rather than delivering those cells externally.

A 2023 study published in Nature Scientific Reports confirmed that synovial chondrogenic potential remains uncompromised in FAI patients, providing biological rationale for this approach: the disease state itself does not appear to impair the cellular repair capacity the scaffold depends on. What ChondroFiller may support is that repair process; published evidence does not support claims of guaranteed cartilage regrowth.

What the clinical evidence shows

The most substantial published dataset comes from Mazek et al. (Journal of Hip Preservation Surgery, 2021), a prospective cohort of 26 adults with FAI-associated acetabular cartilage lesions measuring more than 2 cm². At follow-up ranging from 12 to 60 months, MRI confirmed statistically significant cartilage healing across the group, and 17 of 21 evaluable patients achieved good or excellent results at the 3–5 year mark. Published outcome data for the hip cite Modified Harris Hip Score improvements of approximately 30 points as a representative functional gain. The failure signal in Mazek's cohort was clear: patients with pre-existing Tönnis Grade 2–3 osteoarthritis fared poorly, and two of the 26 participants required total hip replacement during the follow-up period.

A 2025 case report (Journal of Orthopaedic Case Reports) extends the anatomical picture to the femoral head surface, where a 32-year-old man with a 15 mm × 5 mm post-traumatic lesion on the superoanterior weight-bearing dome was treated without microfracture. The reported outcome was complete pain relief, full hip range of motion, and normal gait, with subchondral bone preserved. A single case does not establish a pattern, but it does document ChondroFiller being used successfully at a site distinct from the acetabular rim.

Limitations of the current evidence base

ChondroFiller's evidence in the hip rests on small cohorts and individual cases rather than a large randomised controlled trial; none has been published to date. The outpatient injectable route specifically carries no separate prospective outcome data of its own — current evidence is extrapolated from arthroscopic cohort results, supported by procedural and anatomical reasoning rather than a dedicated injection-route trial.

For patients in the UK, regulatory status is straightforward: ChondroFiller carries CE marking, which covers clinical use in this country.

What ChondroFiller injection does not address

ChondroFiller injection addresses the cartilage damage that FAI creates — it does not reshape the underlying bone. The cam or pincer abnormality that drove the original mechanical contact remains structurally unchanged after the injection, and if impingement forces continue, the repaired cartilage faces the same environment that produced the initial lesion.

This is not a limitation unique to the scaffold; it reflects how FAI works as a two-part problem. The condition involves both an abnormal bone shape and the focal tissue damage that shape produces through repetitive contact over time. Addressing the cartilage without considering the morphology leaves one half of that picture unresolved.

For patients with significant or symptomatic bony impingement, arthroscopic osteoplasty — correcting the femoral head–neck junction or the acetabular rim — may remain part of the overall management plan. Whether that step is necessary depends on the degree of structural deformity and the individual's pattern of symptoms; not every patient with FAI-related cartilage damage requires formal bone correction alongside scaffold repair.

Within the broader treatment pathway, ChondroFiller injection sits between conservative symptom management and more extensive surgical reconstruction. It is a scaffold-based repair option for patients who still have enough healthy joint architecture to make preservation worthwhile — distinct from osteoplasty, which targets the mechanical cause, and from hip replacement, which addresses end-stage joint failure.

Getting assessed at Lincolnshire Hip

Deciding whether ChondroFiller injection is appropriate for a specific hip requires more than matching symptoms to a checklist. The sections above describe the evidence and the patient-selection boundaries in general terms; translating those into an individual answer means a detailed clinical assessment.

That assessment typically involves reviewing a current hip MRI to confirm lesion grade, size, and location; establishing Tönnis staging to rule out advanced joint wear; and working through the full clinical picture — symptom history, prior treatments, activity demands, and whether the underlying FAI morphology warrants separate consideration. The honest outcome of that process might be that ChondroFiller injection is well matched, that a different preservation approach is more appropriate, or that the joint has already progressed beyond what scaffold-based repair can realistically address.

Lincolnshire Hip is led by Professor Paul Y.F. Lee, who was the first clinician in the UK to offer ChondroFiller as an injectable treatment. Consultations take place locally in Sleaford and Grantham, which matters practically for patients across Lincolnshire who have often found specialist hip assessment hard to access without a long journey. The assessment itself is the same regardless of what the eventual recommendation turns out to be.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment.

1. [1] In major joint diseases the human synovium retains its potential to form repair cartilage. (2023). https://doi.org/10.1038/s41598-023-34841-1 https://doi.org/10.1038/s41598-023-34841-1
2. [2] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
3. [3] Femoroacetabular impingement. https://en.wikipedia.org/?curid=20754811 https://en.wikipedia.org/?curid=20754811
4. [4] Both Labral Debridement and Labral Repair Result in >90% Total Hip Arthroplasty-free Survival at 5-Year Follow-Up: An Analysis of the German Cartilage Registry (KnorpelRegister DGOU). (2023). https://doi.org/10.1016/j.arthro.2023.04.014 https://doi.org/10.1016/j.arthro.2023.04.014
5. [5] EP4.2 Arthroscopic Repair of Acetabular Cartilage Delamination Using Chondral Nail Fixation in Femoroacetabular Impingement Patients. (2025). https://doi.org/10.1093/jhps/hnaf011.255 https://doi.org/10.1093/jhps/hnaf011.255
6. [6] Hip Arthroscopy and Chondrofiller Application in Isolated Osteochondral Defect of the Femoral Head. (2025). https://doi.org/10.13107/jocr.2025.v15.i10.6176 https://doi.org/10.13107/jocr.2025.v15.i10.6176